Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: Potential cure for an incurable disease

Expert Opinion on Biological Therapy

Volumn 7, Issue 12, 2007, Pages 1789-1797

  Boyiadzis, Michael ^a   Foon, Kenneth A ^a   Pavletic, Steven ^b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Allogeneic; Autologous; Biologic marker; Chronic lymphocytic leukaemia; Hematopoietic stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; MELPHALAN; PROTEIN KINASE ZAP 70;

CANCER MORTALITY; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; PROGNOSIS; REVIEW; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; EXPERT TESTIMONY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 37049022152     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.12.1789     Document Type: Review

References (78)

1. MATUTES E, WOTHERSPOON A, CATOVSKY D: Differential diagnosis in chronic lymphocytic leukaemia. Best Pract. Res. Clin. Haematol. (2007) 20:367-384.
2. KEATING MJ, KANTARJIAN H, O'BRIEN S et al.: Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. (1991) 9:44-49.
3. MONTSERRAT E, MORENO C, ESTEVE J et al.: How I treat refractory CLL. Blood (2006) 107:1276-1283. • Excellent review on the treatment of refractory CLL.
4. RAI KR, PETERSON BL, APPELBAUM FR et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. (2000) 343:1750-1757.
5. KEATING MJ, O'BRIEN S, ALBITAR M et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23:4079-4088.
6. CHIORAZZI N, RAI KR, FERRARINI M: Chronic lymphocytic leukemia. N. Engl. J. Med. (2005) 352:804-815.
7. PACKHAM G, STEVENSON FK: Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology (2005) 114:441-449.
8. HANADA M, DELIA D, AIELLO A, STADTMAUER E, REED JC: Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood (1993) 82:1820-1828.
9. PEPPER C, BENTLEY P, HOY T: Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. (1996) 95:513-517.
10. PEPPER C, THOMAS A, HOY T, COTTER F, BENTLEY P: Antisense-mediated suppression of bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. (1999) 107:611-615.
11. SCHENA M, LARSSON LG, GOTTARDI D et al.: Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood (1992) 79:2981-2989.
12. CORDONE I, MASI S, MAURO FR et al.: P53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood (1998) 91:4342-4349.
13. DOHNER H, FISCHER K, BENTZ M et al.: P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood (1995) 85:1580-1589.
14. EL ROUBY S, THOMAS A, COSTIN D et al.: P53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of mdr1/mdr3 gene expression. Blood (1993) 82:3452-3459.
15. LOZANSKI G, HEEREMA NA, FLINN IW et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood (2004) 103:3278-3281.
16. STILGENBAUER S, DOHNER H: Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med. (2002) 347:452-453.
17. MOORE JS, PRYSTOWSKY MB, HOOVER RG, BESA EC, NOWELL PC: Defective T cell-mediated, isotype-specific immunoglobulin regulation in B-cell chronic lymphocytic leukemia. Blood (1988) 71:1012-1020.
18. SCRIVENER S, GODDARD RV, KAMINSKI ER, PRENTICE AG: Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk. Lymphoma (2003) 44:383-389.
19. SCRIVENER S, KAMINSKI ER, DEMAINE A, PRENTICE AG: Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br. J. Haematol. (2001) 112:959-964.
20. KAY NE, ZARLING JM: Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood (1984) 63:305-309.
21. ZIEGLER HW, KAY NE, ZARLING JM: Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int. J. Cancer (1981) 27:321-327.
22. ORSINI E, GUARINI A, CHIARETTI S, MAURO FR, FOA R: The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res. (2003) 63:4497-4506.
23. ORSINI E, PASQUALE A, MAGGIO R et al.: Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD 19 cells in vivo and in vitro. Br. J. Haematol. (2004) 125:720-728.
24. H mutation status in CLL.
25. H mutation status in CLL.
26. KROBER A, SEILER T, BENNER A et al.: V(h) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood (2002) 100:1410-1416.
27. OSCIER DG, GARDINER AC, MOULD SJ et al.: Multivariate analysis of prognostic factors in CLL: clinical stage, IgVh gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood (2002) 100:1177-1184.
28. CRESPO M, BOSCH F, VILLAMOR N et al.: Zap-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. (2003) 348:1764-1775.
29. ROSENWALD A, ALIZADEH AA, WIDHOPF G et al.: Relation of gene expression phenotype to immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia. J. Exp. Med. (2001) 194:1639-1647.
30. BOSCH F, MUNTANOLA A, GINE E et al.: Clinical implications of zap-70 expressionin chronic lymphocytic leukemia. Cytom. B Clin. Cytom. (2006) 70:214-217.
31. HAMBLIN TJ, ORCHARD JA, IBBOTSON RE et al.: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood (2002) 99:1023-1029.
32. JELINEK DF, TSCHUMPER RC, GEYER SM et al.: Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br. J. Haematol. (2001) 115:854-861.
33. MATRAI Z, LIN K, DENNIS M et al.: CD38 expression and IgVh gene mutation in B-cell chronic lymphocytic leukemia. Blood (2001) 97:1902-1903.
34. JULIUSSON G, GAHRTON G: Cytogenetics in CLL and related disorders. Baillieres Clin. Haematol. (1993) 6:821-848.
35. HAM BLIN TJ : Prognostic markers in chronic lympocytic leukaemia. Best Pract. Res. Clin. Haematol. (2007) 20:455-468.
36. DOHNER H, STILGENBAUER S, BENNER A et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. (2000) 343:1910-1916. • This study evaluated the chromosomal aberrations in 325 patients with CLL and their prognostic role.
37. STILGENBAUER S, BULLINGER L, LICHTER P, DOHNER H: Genetics of chronic lymphocytic leukemia: genomic aberrations and V(h) gene mutation status in pathogenesis and clinical course. Leukemia (2002) 16:993-1007.
38. SHANAFELT TD, GEYER SM, KAY NE: Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood (2004) 103:1202-1210.
39. STAUDT LM: Gene expression profiling of lymphoid malignancies. Annu. Rev. Med. (2002) 53:303-318.
40. STAUDT LM: Molecular diagnosis of the hematologic cancers. N. Engl. J. Med. (2003) 348:1777-1785.
41. BEN-BASSAT I, RAANANI P, GALE RP: Graft-versus-leukemia in chronic lymphocytic leukemia. Bone Marrow Transplant. (2007) 39:441-446.
42. PAVLETIC ZS, BIERMAN PJ, VOSE JM et al.: High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann. Oncol. (1998) 9:1023-1026.
43. DREGER P, VAN BIEZEN A, BRAND R et al.: Prognostic factors for survival after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): the EBMT experience. Blood (2000) 96:A482-A482.
44. DREGER P, BUSCH R, STILGENBAUER S et al.: Early autologous stem cell transplantation (set) in genetically poor-risk chronic lymphocytic leukemia is feasible and effective: results from a prospective multicenter study (GCLLSG CLL3 protocol). Blood (2004) 104:A45.
45. DREGER P, STILGENBAUER S, BENNER A et al.: The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the Vh gene mutational status. Blood (2004) 103:2850-2858.
46. RITGEN M, LANGE A, STILGENBAUER S et al.: Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood (2003) 101:2049-2053.
47. SCHLOE U, VIEHMANN K, LANGE A, RITGEN M, DREGER P: CD38 expression has no prognostic influence after autologous stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL). Bone Marrow Transplant. (2002) 29:S165.
48. PAULUS U, SCHMITZ N, VIEHMANN K, VON NEUHOFF N, DREGER P: Combined positive/negative selection for highly effective purging of pbpc grafts: towards clinical application in patients with B-CLL. Bone Marrow Transplant. (1997) 20:415-420.
49. BERKAHN L, SIMPSON D, RAPTIS A, KLINGEMANN HG: In vivo purging with rituximab prior to collection of stem cells for autologous transplantation in chronic lymphocytic leukemia. J. Hematother. Stem Cell Res. (2002) 11:315-320.
50. BUCKSTEIN R, IMRIE K, SPANER D et al.: Stem cell function and engraftment is not affected by "In vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin. Oncol. (1999) 26:115-122.
51. MONTILLO M, TEDESCHI A, MIQUELEIZ S et al.: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J. Clin. Oncol. (2006) 24:2337-2342.
52. DREGER P, VIEHMANN K, VON NEUHOFF N et al.: A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. Exp. Hematol. (2000) 28:1187-1196.
53. MICHALLET M, THIEBAUT A, DREGER P et al.: Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the european blood and marrow transplantation (EBMT) CLL subcommittee on behalf of the EBMT chronic leukaemias working party (CLWP). Br. J. Haematol. (2000) 108:595-601.
54. PAVLETIC S, ZHOU GM, SOBOCINSKI K et al.: Genetically identical twin transplantation for chronic lymphocytic leukemia. Leukemia (2007) (In Press).
55. GINE E, MORENO C, ESTEVE J, MONTSERRAT E: The role of stem-cell transplantation in chronic lympocytic leukemia risk-adapted therapy. Best Pract. Res. Clin. Haematol. (2007) 20:529-543.
56. MORENO C, VILLAMOR N, COLOMER D et al.: Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated Vh gene in patients with chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23:3433-3438.
57. DEMAGALHAES-SILVERMAN M, DONNENBERG A, HAMMERT L et al.: Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia. Bone Marrow Transplant. (1997) 20:175-177.
58. ESPANOL I, BUCHLER T, FERRA C et al.: Richter's syndrome after allogeneic stem cell transplantation for chronic lymphocytic leukaemia successfully treated by withdrawal of immunosuppression, and donor lymphocyte infusion. Bone Marrow Transplant. (2003) 31:215-218.
59. RONDON G, GIRALT S, HUH Y et al.: Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant. (1996) 18:669-672.
60. MEHTA J, POWLES R, SINGHAL S et al.: Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia. Bone Marrow Transplant. (1996) 17:371-375.
61. DREGER P, RITGEN M, BOTTCHER S, SCHMITZ N, KNEBA M: The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? Leukemia (2005) 19:1135-1138.
62. MORENO C, VILLAMOR N, COLOMER D et al.: Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood (2006) 107:4563-4569.
63. MATTSSON J, UZUNEL M, REMBERGER M et al.: Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia (2000) 14:247-254.
64. RITGEN M, STILGENBAUER S, VON NEUHOFF N et al.: Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood (2004) 104:2600-2602.
65. DREGER P, BRAND R, MILLIGAN D et al.: Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia (2005) 19:1029-1033.
66. KHARFAN-DABAJA MA, ANASETTI C, SANTOS ES: Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. Biol. Blood Marrow Transplant. (2007) 13:373-385.
67. GRIBBEN JG: Stem-cell transplantation in chronic lympocytic leukaemia. Best Pract. Res. Clin. Haematol. (2007) 20:513-527.
68. DREGER P, CORRADINI P, KIMBY E et al.: Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia (2007) 21:12-17. •• An expert consensus of the role of allo-HSCT in CLL.
69. GRIBBEN JG, ZAHRIEH D, STEPHANS K et al.: Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood (2005) 106:4389-4396.
70. MILLIGAN DW, FERNANDES S, DASGUPTA R et al.: Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood (2005) 105:397-404.
71. MONTSERRAT E, ESTEVE J, SCHMITZ N et al.: Autologous stem-cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL): results in 107 patients. Blood (1999) 94:A397-A397.
72. PAVLETIC ZS, ARROWSMITH ER, BIERMAN PJ et al.: Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. (2000) 25:717-722.
73. TOZE CL, GALAL A, BARNETT MJ, SHEPHERD JD et al.: Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplant. (2005) 36:825-830.
74. PAVLETIC SZ, KHOURI IF, HAAGENSON M et al.: Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the center for international blood and marrow transplant research. J. Clin. Oncol. (2005) 23:5788-5794.
75. SORROR ML, MARIS MB, SANDMAIER BM et al.: Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23:3819-3829.
76. DELGADO J, THOMSON K, RUSSELL N et al.: Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British society of blood and marrow transplantation study. Blood (2006) 107:1724-1730.
77. BROWN JR, KIM HT, LI S et al.: Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol. Blood Marrow Transplant. (2006) 12:1056-1064.
78. CABALLERO D, GARCIA-MARCO JA, MARTINO R et al.: Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin. Cancer Res. (2005) 11:7757-7763.